HK1245678A1 - 使用酪氨酸激酶抑制剂的组合物和方法 - Google Patents

使用酪氨酸激酶抑制剂的组合物和方法 Download PDF

Info

Publication number
HK1245678A1
HK1245678A1 HK18105513.7A HK18105513A HK1245678A1 HK 1245678 A1 HK1245678 A1 HK 1245678A1 HK 18105513 A HK18105513 A HK 18105513A HK 1245678 A1 HK1245678 A1 HK 1245678A1
Authority
HK
Hong Kong
Prior art keywords
methods
tyrosine kinase
phosphorylation
compositions
tyrosine
Prior art date
Application number
HK18105513.7A
Other languages
English (en)
Chinese (zh)
Inventor
Anton BENNETT
Jae-Sung Yi
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of HK1245678A1 publication Critical patent/HK1245678A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18105513.7A 2015-01-26 2016-01-26 使用酪氨酸激酶抑制剂的组合物和方法 HK1245678A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US62/107,553 2015-01-26
US201562250052P 2015-11-03 2015-11-03
US62/250,052 2015-11-03
PCT/US2016/014882 WO2016123086A1 (en) 2015-01-26 2016-01-26 Compositions and methods of using tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1245678A1 true HK1245678A1 (zh) 2018-08-31

Family

ID=56544226

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105513.7A HK1245678A1 (zh) 2015-01-26 2016-01-26 使用酪氨酸激酶抑制剂的组合物和方法

Country Status (7)

Country Link
US (4) US10471059B2 (enExample)
EP (2) EP4653015A3 (enExample)
JP (4) JP6854766B2 (enExample)
CN (2) CN107530298B (enExample)
HK (1) HK1245678A1 (enExample)
MX (2) MX2017009643A (enExample)
WO (1) WO2016123086A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
EP3823615A4 (en) * 2018-06-18 2022-04-06 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
WO2020117962A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020174420A1 (en) * 2019-02-27 2020-09-03 Astrazeneca Ab Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2022125551A1 (en) * 2020-12-07 2022-06-16 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
WO2023175136A1 (en) * 2022-03-18 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
CN116832040A (zh) * 2023-06-12 2023-10-03 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025031474A1 (en) * 2023-08-10 2025-02-13 Insilico Medicine Ip Limited Method and medicament for treating endometriosis
WO2025111752A1 (zh) * 2023-11-27 2025-06-05 中山大学 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
WO2025170008A1 (ja) * 2024-02-07 2025-08-14 国立大学法人京都大学 成熟心筋細胞の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
CA2388343A1 (en) * 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2008512484A (ja) * 2004-09-09 2008-04-24 ザ ジェネラル ホスピタル コーポレーション 心臓細胞におけるホスファターゼ活性の調節
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007047919A2 (en) * 2005-10-20 2007-04-26 University Of South Florida Treatment of restenosis and stenosis with dasatinib
GB0609962D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CN103463621B (zh) * 2006-10-31 2016-01-06 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
US9050368B2 (en) * 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CA2897538A1 (en) * 2013-01-10 2014-07-17 Pulmokine, Inc. Therapeutic indications of kinase inhibitors
CA2917667A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Also Published As

Publication number Publication date
US11458137B2 (en) 2022-10-04
US20200009142A1 (en) 2020-01-09
JP2025061369A (ja) 2025-04-10
WO2016123086A1 (en) 2016-08-04
US20230036788A1 (en) 2023-02-02
US10471059B2 (en) 2019-11-12
MX2022012505A (es) 2022-11-07
CA2974958A1 (en) 2016-08-04
CN113244399A (zh) 2021-08-13
JP2021050218A (ja) 2021-04-01
JP2018504416A (ja) 2018-02-15
EP3250192A4 (en) 2018-09-26
CN107530298B (zh) 2021-06-04
MX2017009643A (es) 2018-05-04
JP2023052878A (ja) 2023-04-12
EP3250192A1 (en) 2017-12-06
EP4653015A2 (en) 2025-11-26
EP3250192B1 (en) 2025-10-08
CN107530298A (zh) 2018-01-02
JP6854766B2 (ja) 2021-04-07
EP4653015A3 (en) 2025-12-31
US20250360129A1 (en) 2025-11-27
US20180271864A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
HK1245678A1 (zh) 使用酪氨酸激酶抑制剂的组合物和方法
IL281805A (en) Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use
WO2007115289A8 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
EP3572414A4 (en) COMPOUND USED AS A BRUTON TYROSINE KINASE INHIBITOR, PROCESS OF PREPARATION AND APPLICATION
SG11202104460UA (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
EP4338802A3 (en) Tyk2 inhibitors, uses, and methods for production thereof
EP4364795A3 (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
EP4435105A3 (en) Asgr inhibitors for reduzing cholesterol levels
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
HK1255163A1 (zh) 作为apj受体激动剂的杂芳基羟基嘧啶酮
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2013010136A3 (en) Inhibitors of bruton's tyrosine kinase
NZ730771A (en) Aurora a kinase inhibitor
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
EP4295910A3 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
WO2008061108A3 (en) Phthalazine derivatives
WO2018218197A3 (en) ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
WO2016183009A3 (en) Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna